In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/adding-lenvatinib-pembro-ups-pfs-head-and-neck-cancer-2026a10008jn?src=rss
Author :
Publish date : 2026-03-20 11:50:00
Copyright for syndicated content belongs to the linked Source.
